Core Viewpoint - The company, Xiansheng Pharmaceutical, has received approval from the National Medical Products Administration of China for clinical trials of its self-developed anti-tumor candidate drug SIM0609, targeting advanced solid tumors [1] Group 1: Drug Development - SIM0609 is a novel antibody-drug conjugate (ADC) targeting Cadherin 17 (CDH17), which is highly expressed in various cancers, including gastric cancer, colorectal cancer, and pancreatic cancer [1] - The drug is composed of a humanized monoclonal antibody linked to a proprietary soluble cleavable linker and a novel topoisomerase I inhibitor developed by the company [1] Group 2: Clinical Trial Focus - The clinical trials will focus on advanced solid tumors, particularly gastrointestinal tumors, highlighting the potential of CDH17 as a therapeutic target [1]
先声药业(02096.HK)获药物临床试验批准通知书